Icon (NASDAQ:ICLR) Sets New 1-Year High After Earnings Beat

Key Points

• ICON reached a new 52-week high after reporting adjusted EPS of $2.66, exceeding the $2.62 consensus, while quarterly revenue of approximately $2.02 billion also topped expectations.
• Management raised its 2026 outlook and cited a roughly $24.5 billion backlog, but revenue declined 0.9% year over year and EPS fell from $3.31 in the prior-year quarter, indicating continued profitability pressure.
• The stock’s consensus rating remains Hold, with an average price target of $174.73, below its reported trading level near $203.49; ICON also issued $2.15 billion of notes and redeemed about 2.36 million shares.

Icon Plc (NASDAQ:ICLR - Get Free Report) reached a new 52-week high on Wednesday following a better than expected earnings announcement. The stock traded as high as $207.74 and last traded at $203.4880, with a volume of 1,468,341 shares changing hands. The stock had previously closed at $182.98.

The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.62 by $0.04. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon's revenue was down .9% compared to the same quarter last year. During the same period last year, the business posted $3.31 EPS.

More Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: ICON reported third-quarter adjusted earnings of $2.66 per share, ahead of estimates ranging from $2.62 to $2.64, while revenue of approximately $2.02 billion also exceeded expectations. ICON Q3 earnings and revenues beat estimates
• Positive Sentiment: Management raised its 2026 outlook, signaling improved confidence in operating performance despite ongoing pressure on earnings and revenue. The company also reported a roughly $24.5 billion backlog, supporting future demand visibility. ICON Q3 non-GAAP earnings and revenue
• Positive Sentiment: ICON completed a $2.15 billion note issuance and redeemed approximately 2.36 million shares during the third quarter. The share redemption can support per-share results and indicates continued capital allocation toward buybacks, although the new debt increases financing obligations. ICON completes note issuance and share redemption
• Neutral Sentiment: Short-interest data showed no reported shares sold short as of October 26, suggesting limited evidence of a short-covering-driven move, though the reported figure may reflect data limitations.
• Negative Sentiment: Third-quarter revenue declined about 0.9% year over year, while adjusted EPS fell from $3.31 a year earlier. This indicates that the earnings beat was measured against lowered expectations and that profitability remains under pressure. ICON third-quarter earnings results
• Neutral Sentiment: Chief Accounting Officer Emer Lyons sold 272 shares to cover tax withholding tied to vested equity awards. The relatively small, tax-related transaction is unlikely to materially affect investor sentiment. ICON CAO stock sale

Analysts Set New Price Targets

Several brokerages have recently issued reports on ICLR. UBS Group initiated coverage on shares of Icon in a research note on Wednesday, September 30th. They issued a "neutral" rating and a $195.00 price objective on the stock. Truist Financial reissued a "buy" rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a report on Friday, July 31st. Robert W. Baird set a $194.00 price target on shares of Icon in a research report on Friday, July 31st. Bank of America upgraded shares of Icon from an "underperform" rating to a "neutral" rating and set a $185.00 price target on the stock in a research report on Friday, October 9th. Finally, William Blair upgraded shares of Icon to a "strong-buy" rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $174.73.

Insider Buying and Selling at Icon

In other news, Director Ronan Murphy sold 5,005 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $175.00, for a total value of $875,875.00. Following the completion of the transaction, the director owned 3,847 shares in the company, valued at approximately $673,225. This represents a 56.54% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ciaran Murray sold 2,677 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the transaction, the director directly owned 20,452 shares of the company's stock, valued at $3,360,059.08. The trade was a 11.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 23,068 shares of company stock valued at $3,936,744 in the last quarter. 44.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Icon

Several institutional investors have recently made changes to their positions in ICLR. Principal Financial Group Inc. lifted its stake in Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company's stock worth $366,481,000 after purchasing an additional 310,236 shares during the period. Trinity Street Asset Management LLP raised its holdings in shares of Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company's stock worth $266,725,000 after buying an additional 327,314 shares in the last quarter. Maple Rock Capital Partners Inc. raised its holdings in shares of Icon by 257.8% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company's stock worth $208,383,000 after buying an additional 864,300 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Icon by 50.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company's stock worth $87,262,000 after buying an additional 265,858 shares in the last quarter. Finally, Sound Shore Management Inc. CT bought a new position in shares of Icon during the 1st quarter worth approximately $69,379,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Price Performance

The company has a 50-day moving average of $169.42 and a 200 day moving average of $146.06. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The firm has a market cap of $15.63 billion, a P/E ratio of 47.92, a P/E/G ratio of 11.98 and a beta of 1.24.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.